Many of the generic manufacturers started years back with knock off drugs to sell locally in India, but now the game is changing to where US Pharma is using some of the talent, which costs less than R and D individuals here in the states, to further develop existing work, in other words somewhat continue...
Posted to
The Medical Quack .... by Barbara Duck
on 09-05-2008
Filed under: Medically Related, Pharma/FDA News, Genomics, drugs, Pharma, Biotech, Cancer, FDA, Budgets, R and D, Alzheimers, Outsourcing
Intellectual Property on the auction block, patents with FDA approval. This is the first time I have noticed technology with health care just up on the open auction block, especially as it relates to cancer research. With the acquisition, it must not fit into the same business model...
Pfizer is wasting no time to get the calculations running and numbers rolling. To stay in the market, they are attempting to find out as much as they can about potential side effects and other perhaps adverse affects of their drugs. Better than they find up them front, as it will make for better...
Posted to
The Medical Quack .... by Barbara Duck
on 07-15-2008
Filed under: Medically Related, Technology, Pharma/FDA News, personalized medicine, DNA, drugs, Biotech, Pharmacogenomics, Side Effects
Update: Are 3 minds better than one? It certainly appears this could be the case, at least when it comes to clinical trials and getting the right type of participants to enroll and some forecasting to make sure the drugs will succeed. What is the target here, the big crystal...
Good insight and commentary here from the "inside" track...are members of Congress helping or stalling the progression of the FDA... will the Biotechs be able to develop and withstand some of the stringencies and additional methodologies to bring new products to market to save lives? Nice to...